The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway
Raphaël Ognar discusses the results we have seen in the NK space over recent years and how NKILT is targeting a novel pathway with its Chimeric ILT-Receptor (CIR) binding technology.